Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 350,100 shares, an increase of 31.6% from the February 28th total of 266,100 shares. Based on an average trading volume of 604,700 shares, the days-to-cover ratio is […]
Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) and Valneva (NASDAQ:VALN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Insider & Institutional Ownership 4.7% of Evaxion Biotech A/S […]
Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and infectious […]
Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 9,400 shares, a decline of 34.7% from the March 31st total of 14,400 shares. Based on an average daily volume of 54,000 shares, the short-interest ratio is […]
Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday, Zacks.com reports. According to Zacks, “Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and […]